Royalty Pharma (RPRX) Cash & Equivalents Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) Cash & Equivalents Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 13.29% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.63% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -16.07% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.88% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 47.78% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Royalty Pharma | 25.71 Bn | 25.10 Bn | - | -33.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.30% |
| Dec 31, 2025 | -28.75% |
| Sep 30, 2025 | -1.80% |
| Jun 30, 2025 | -33.07% |
| Mar 31, 2025 | -15.32% |
| Dec 31, 2024 | -15.52% |
| Sep 30, 2024 | -19.20% |
| Jun 30, 2024 | 15.60% |
| Mar 31, 2024 | 5.95% |
| Dec 31, 2023 | -22.09% |
| Sep 30, 2023 | -15.51% |
| Jun 30, 2023 | -3.83% |
| Mar 31, 2023 | 189.44% |
| Dec 31, 2022 | 262.46% |